<DOC>
	<DOCNO>NCT01051752</DOCNO>
	<brief_summary>A prospective observational study pharmacokinetic pharmacodynamic parameter evaluate cohort patient NTM disease .</brief_summary>
	<brief_title>PK PD Drugs Nontuberculous Mycobacterial Diseases Dutch Patients</brief_title>
	<detailed_description>NTM widely distribute environment especially find soil water source . These bacteria similar tuberculosis bacteria . We long aware bacteria cause illness . Especially patient chronic lung disease sensitive bacteria susceptible develop infection . A lot ambiguity consist best treatment infection . Up till mainly normal treatment tuberculosis use , however , time period medicine use dose use mainly unknown . To investigate whether dose use moment right pharmacokinetic curve take steady-state .</detailed_description>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<criteria>currently treat NTM infection recently diagnose NTM infection start treatment University Centre Chronic Diseases Dekkerswald ( Groesbeek ) , Centre Revalidation Beatrixoord ( Haren ) , outpatient clinic The Netherlands . Diagnosis treatment accord American Thoracic Society ( ATS ) criteria NTM infection . Patients pulmonary NTM infection ( possible extrapulmonary localization well ) eligible Treated least rifampicin ethambutol optionally isoniazid , clarithromycin azithromycin daily basis Age least 18 year Patient use drug least two week steady state concentration use drug expect Informed consent sign The medical state patient allow inclusion accord physician attendance . The patient ' clinical parameter urge immediate cessation drug . The patient pregnant . Significant hepatic renal dysfunction base chemistry parameter ( grade 1 accord international adverse event grade system , see http : /ctep.cancer.gov ) symptomatic liver dysfunction ( nausea vomit ) . Patients cystic fibrosis , since show deviate pharmacokinetics many drug . Patients HIV infection , since may show deviate pharmacokinetics drug use NTM disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Nontuberculous mycobacterial disease</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>